MYEOV expression inhibitor, pharmaceutical composition and application of MYEOV expression inhibitor in preparation of pancreatic cancer gemcitabine drug resistance resisting drugs

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
By combining the MYEOV expression inhibitor shRNA with gemcitabine, the problem of gemcitabine resistance in pancreatic cancer chemotherapy was solved, the chemotherapy effect was improved, and the survival of patients was prolonged.

CN122038403APending Publication Date: 2026-05-15HANGZHOU FIRST PEOPLES HOSPITAL

0 Cites 0 Cited by

Patent Information

Application Number: CN202610286007.7
Authority / Receiving Office: CN · China
Patent Type: Applications(China)
Current Assignee / Owner
Filing Date: 2026-03-10
Publication Date: 2026-05-15

Application Information

Patent Timeline

10 Mar 2026

Application

CN202610286007.7

15 May 2026

Publication

CN122038403A

IPC: C12N15/113; A61K31/7068; A61K31/7088; A61P35/00; A61P1/18

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Organic active ingredients Digestive system

Technology Topics

Gemcitabine resistancePancreas Cancers

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Gemcitabine's efficacy in chemotherapy for pancreatic cancer is limited due to drug resistance issues, and patient prognosis improvement is not significant.

Method used

By using MYEOV expression inhibitor shRNA, MYEOV expression is knocked out or inhibited, and then combined with gemcitabine, a drug to treat gemcitabine-resistant pancreatic cancer was prepared.

Benefits of technology

It reduces the resistance of pancreatic cancer to gemcitabine, improves chemotherapy sensitivity, and significantly prolongs patient survival.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The invention discloses an MYEOV expression inhibitor, a pharmaceutical composition and application of the MYEOV expression inhibitor and the pharmaceutical composition in preparation of pancreatic cancer gemcitabine resistance drugs, and relates to the technical field of biology, in particular to the MYEOV expression inhibitor which is shRNA, and the nucleotide sequence of the shRNA is shown as SEQ ID NO.1. The invention further discloses an application of the MYEOV expression inhibitor and the pharmaceutical composition in preparation of pancreatic cancer gemcitabine resistance drugs. By knocking out or inhibiting the expression of MYEOV, the drug resistance of pancreatic cancer to a chemotherapeutic drug gemcitabine can be weakened.

Need to check novelty before this filing date? Find Prior Art